Final analysis of the phase II DEEPER trial in RAS wild-type metastatic colorectal cancer: m-FOLFOXIRI plus cetuximab vs bevacizumab showed no difference in PFS or OS in the per-protocol set; benefit signals were confined to exploratory subgroups.
RCT
Sunakawa et al. Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial